Related Experiment Video
Updated: Aug 30, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
Underidentification and undertreatment issues
1University of Cincinnati College of Pharmacy, 3223 Eden Ave. Loc #4, Cincinnati, OH 45267-0004, USA. Michael.Bottorff@UC.edu
Insights
Despite guidelines, many patients with high cholesterol remain undiagnosed or undertreated, failing to reach treatment goals. Improving dyslipidemia diagnosis and treatment is crucial for reducing coronary heart disease (CHD) risk.
Area of Science:
- Cardiology
- Public Health
- Pharmacology
Background:
- Coronary heart disease (CHD) is a major cause of morbidity and mortality.
- Adult Treatment Panel (ATP) guidelines recommend cholesterol reduction for CHD risk management.
- Despite evidence, significant gaps exist in dyslipidemia diagnosis and treatment.
Purpose of the Study:
- To highlight the challenges in diagnosing and treating dyslipidemia.
- To emphasize the need for improved adherence to cholesterol management guidelines.
- To underscore the importance of achieving therapeutic targets for low-density lipoprotein cholesterol (LDL-C).
Main Methods:
- Review of Adult Treatment Panel (ATP) guidelines and related data.
- Analysis of patient eligibility for lipid modification.
- Examination of current diagnosis, treatment, and persistence rates for dyslipidemia.
Main Results:
- Over 65 million Americans are eligible for lipid modification.
- Approximately 50% of patients do not have cholesterol assessed.
- Less than 45% receive lipid-modifying therapy, and over 75% fail to reach LDL-C goals.
- Fewer than 30% persist with therapy beyond one year.
Conclusions:
- Current diagnosis and treatment rates for dyslipidemia are insufficient to reduce CHD risk.
- Improved detection and adherence to therapeutic targets are necessary.
- Addressing treatment persistence is critical for effective CHD prevention.
Abstract:
Despite the Adult Treatment Panel (ATP) guidelines and strong evidence that reduction of blood cholesterol levels favorably decreases the morbidity and mortality associated with coronary heart disease (CHD), a significant number of patients remain undiagnosed and untreated. With the aggressive detection and evaluation methods ATP III advocates, more than 65 million Americans are now eligible for lipid modification through lifestyle changes and/or drug therapy. Recent data suggest, however, that as many as 50% of all patients do not have their cholesterol assessed and less than 45% receive lipid-modifying therapy. Additionally, more than 75% of patients who receive therapy fail to achieve their National Cholesterol Education Program (NCEP) target low-density lipoprotein cholesterol goal. Persistence with therapy is another challenge, as less than 30% of patients continue with therapy beyond one year. If a realistic attempt is to be made to reduce the CHD risk among Americans, diagnosis of dyslipidemia and treatment to therapeutic targets must be improved.
Related Concept Videos
Anorexia Nervosa
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
Stereotypes, Prejudice, and Discrimination
Ethical Issues
Ethical Concerns in Healthcare:
Stereotype Threat and Self-fulfilling Prophecies
Documentation of Nursing Diagnosis
In some settings, data-driven computerized decision support systems are in place, allowing for more accurate nursing diagnoses. The database within one of these systems includes diagnostic labels defining characteristics, activities, and indicators for nursing. A nurse enters assessment...
Stereotype Content Model
